327 related articles for article (PubMed ID: 23158536)
1. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
Chen J; Long JB; Hurria A; Owusu C; Steingart RM; Gross CP
J Am Coll Cardiol; 2012 Dec; 60(24):2504-12. PubMed ID: 23158536
[TBL] [Abstract][Full Text] [Related]
2. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
Pinder MC; Duan Z; Goodwin JS; Hortobagyi GN; Giordano SH
J Clin Oncol; 2007 Sep; 25(25):3808-15. PubMed ID: 17664460
[TBL] [Abstract][Full Text] [Related]
3. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
Bowles EJ; Wellman R; Feigelson HS; Onitilo AA; Freedman AN; Delate T; Allen LA; Nekhlyudov L; Goddard KA; Davis RL; Habel LA; Yood MU; McCarty C; Magid DJ; Wagner EH;
J Natl Cancer Inst; 2012 Sep; 104(17):1293-305. PubMed ID: 22949432
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure.
Seicean S; Seicean A; Alan N; Plana JC; Budd GT; Marwick TH
Circ Heart Fail; 2013 May; 6(3):420-6. PubMed ID: 23425978
[TBL] [Abstract][Full Text] [Related]
5. Lack of uniformity in cardiac assessment during trastuzumab therapy.
Subar M; Lin W; Chen W; Pittman DG
Breast J; 2011; 17(4):383-90. PubMed ID: 21615821
[TBL] [Abstract][Full Text] [Related]
6. [Heart failure in women treated with adjuvant trastuzumab for breast cancer].
Tarantini L; Feola M; Albini A; Gori S; Foglietta J; Cicoira MA; Pulignano G
G Ital Cardiol (Rome); 2012 May; 13(5 Suppl 1):54S-62S. PubMed ID: 23678535
[TBL] [Abstract][Full Text] [Related]
7. Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study.
Sawaki M; Mukai H; Tokudome N; Nakayama T; Taira N; Mizuno T; Yamamoto Y; Horio A; Watanabe T; Uemura Y; Ohashi Y
Breast Cancer; 2012 Jul; 19(3):253-8. PubMed ID: 21526424
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
9. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer.
Du XL; Xia R; Liu CC; Cormier JN; Xing Y; Hardy D; Chan W; Burau K
Cancer; 2009 Nov; 115(22):5296-308. PubMed ID: 19672997
[TBL] [Abstract][Full Text] [Related]
10. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials.
Russell SD; Blackwell KL; Lawrence J; Pippen JE; Roe MT; Wood F; Paton V; Holmgren E; Mahaffey KW
J Clin Oncol; 2010 Jul; 28(21):3416-21. PubMed ID: 20530275
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.
Tarantini L; Cioffi G; Gori S; Tuccia F; Boccardi L; Bovelli D; Lestuzzi C; Maurea N; Oliva S; Russo G; Faggiano P;
J Card Fail; 2012 Feb; 18(2):113-9. PubMed ID: 22300778
[TBL] [Abstract][Full Text] [Related]
13. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.
Seicean S; Seicean A; Plana JC; Budd GT; Marwick TH
J Am Coll Cardiol; 2012 Dec; 60(23):2384-90. PubMed ID: 23141499
[TBL] [Abstract][Full Text] [Related]
14. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
Bengala C; Zamagni C; Pedrazzoli P; Matteucci P; Ballestrero A; Da Prada G; Martino M; Rosti G; Danova M; Bregni M; Jovic G; Guarneri V; Maur M; Conte PF;
Br J Cancer; 2006 Apr; 94(7):1016-20. PubMed ID: 16570045
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant trastuzumab for breast cancer. A second look. Longer follow-up confirms improved overall survival.
Prescrire Int; 2012 Dec; 21(133):285-7. PubMed ID: 23373091
[TBL] [Abstract][Full Text] [Related]
16. [Cardiotoxicity of trastuzumab of significance in the adjuvant treatment of breast cancer].
Menke-van der Houven van Oordt CW; Fliervoet HJ; Mandigers CM; van Spronsen DJ
Ned Tijdschr Geneeskd; 2008 Jan; 152(3):158-63. PubMed ID: 18271465
[TBL] [Abstract][Full Text] [Related]
17. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
Procter M; Suter TM; de Azambuja E; Dafni U; van Dooren V; Muehlbauer S; Climent MA; Rechberger E; Liu WT; Toi M; Coombes RC; Dodwell D; Pagani O; Madrid J; Hall M; Chen SC; Focan C; Muschol M; van Veldhuisen DJ; Piccart-Gebhart MJ
J Clin Oncol; 2010 Jul; 28(21):3422-8. PubMed ID: 20530280
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab-induced cardiomyopathy.
Guglin M; Cutro R; Mishkin JD
J Card Fail; 2008 Jun; 14(5):437-44. PubMed ID: 18514938
[TBL] [Abstract][Full Text] [Related]
19. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study.
Wadhwa D; Fallah-Rad N; Grenier D; Krahn M; Fang T; Ahmadie R; Walker JR; Lister D; Arora RC; Barac I; Morris A; Jassal DS
Breast Cancer Res Treat; 2009 Sep; 117(2):357-64. PubMed ID: 19082707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
